vs
Consolidated Water Co. Ltd.（CWCO）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Consolidated Water Co. Ltd.的1.0倍（$30.3M vs $29.6M），Consolidated Water Co. Ltd.净利率更高（10.3% vs -221.3%，领先231.6%），REGENXBIO Inc.同比增速更快（43.0% vs 4.4%），Consolidated Water Co. Ltd.自由现金流更多（$3.4M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -13.6%）
可口可乐联合装瓶公司总部位于美国北卡罗来纳州夏洛特市，是美国规模最大的独立可口可乐装瓶企业，主要承担可口可乐系列饮品的生产装瓶、仓储配送与市场销售业务，在美国本土饮品供应链中占据重要地位。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CWCO vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.0倍
$29.6M
营收增速更快
RGNX
高出38.6%
4.4%
净利率更高
CWCO
高出231.6%
-221.3%
自由现金流更多
CWCO
多$56.2M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-13.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $29.6M | $30.3M |
| 净利润 | $3.0M | $-67.1M |
| 毛利率 | 34.7% | — |
| 营业利润率 | 9.1% | -190.0% |
| 净利率 | 10.3% | -221.3% |
| 营收同比 | 4.4% | 43.0% |
| 净利润同比 | 91.5% | -31.2% |
| 每股收益（稀释后） | $0.18 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CWCORGNX
| Q4 25 | $29.6M | $30.3M | ||
| Q3 25 | $35.1M | $29.7M | ||
| Q2 25 | $33.6M | $21.4M | ||
| Q1 25 | $33.7M | $89.0M | ||
| Q4 24 | $28.4M | $21.2M | ||
| Q3 24 | $33.4M | $24.2M | ||
| Q2 24 | $32.5M | $22.3M | ||
| Q1 24 | $39.7M | $15.6M |
净利润CWCORGNX
| Q4 25 | $3.0M | $-67.1M | ||
| Q3 25 | $5.5M | $-61.9M | ||
| Q2 25 | $5.1M | $-70.9M | ||
| Q1 25 | $4.8M | $6.1M | ||
| Q4 24 | $1.6M | $-51.2M | ||
| Q3 24 | $4.5M | $-59.6M | ||
| Q2 24 | $15.9M | $-53.0M | ||
| Q1 24 | $6.5M | $-63.3M |
毛利率CWCORGNX
| Q4 25 | 34.7% | — | ||
| Q3 25 | 36.9% | — | ||
| Q2 25 | 38.2% | — | ||
| Q1 25 | 36.5% | — | ||
| Q4 24 | 29.9% | 70.2% | ||
| Q3 24 | 34.8% | 48.8% | ||
| Q2 24 | 35.8% | 52.5% | ||
| Q1 24 | 35.0% | 72.6% |
营业利润率CWCORGNX
| Q4 25 | 9.1% | -190.0% | ||
| Q3 25 | 16.4% | -176.3% | ||
| Q2 25 | 15.7% | -296.3% | ||
| Q1 25 | 13.7% | 13.6% | ||
| Q4 24 | 3.8% | -242.1% | ||
| Q3 24 | 14.6% | -256.6% | ||
| Q2 24 | 15.4% | -251.3% | ||
| Q1 24 | 18.4% | -408.8% |
净利率CWCORGNX
| Q4 25 | 10.3% | -221.3% | ||
| Q3 25 | 15.8% | -208.3% | ||
| Q2 25 | 15.2% | -331.8% | ||
| Q1 25 | 14.2% | 6.8% | ||
| Q4 24 | 5.6% | -241.3% | ||
| Q3 24 | 13.3% | -246.3% | ||
| Q2 24 | 48.8% | -237.7% | ||
| Q1 24 | 16.3% | -405.4% |
每股收益（稀释后）CWCORGNX
| Q4 25 | $0.18 | $-1.30 | ||
| Q3 25 | $0.34 | $-1.20 | ||
| Q2 25 | $0.32 | $-1.38 | ||
| Q1 25 | $0.30 | $0.12 | ||
| Q4 24 | $0.10 | $-0.99 | ||
| Q3 24 | $0.28 | $-1.17 | ||
| Q2 24 | $0.99 | $-1.05 | ||
| Q1 24 | $0.40 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $123.8M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $221.7M | $102.7M |
| 总资产 | $257.6M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CWCORGNX
| Q4 25 | $123.8M | $230.1M | ||
| Q3 25 | $123.6M | $274.2M | ||
| Q2 25 | $112.2M | $323.3M | ||
| Q1 25 | $107.9M | $267.9M | ||
| Q4 24 | $99.4M | $234.7M | ||
| Q3 24 | $104.9M | $255.5M | ||
| Q2 24 | $96.7M | $290.4M | ||
| Q1 24 | $46.2M | $338.7M |
股东权益CWCORGNX
| Q4 25 | $221.7M | $102.7M | ||
| Q3 25 | $220.4M | $161.5M | ||
| Q2 25 | $216.6M | $213.7M | ||
| Q1 25 | $213.3M | $274.2M | ||
| Q4 24 | $210.0M | $259.7M | ||
| Q3 24 | $209.8M | $301.4M | ||
| Q2 24 | $206.7M | $348.3M | ||
| Q1 24 | $192.1M | $390.7M |
总资产CWCORGNX
| Q4 25 | $257.6M | $453.0M | ||
| Q3 25 | $257.2M | $525.2M | ||
| Q2 25 | $257.5M | $581.0M | ||
| Q1 25 | $250.4M | $490.9M | ||
| Q4 24 | $243.3M | $466.0M | ||
| Q3 24 | $238.4M | $519.1M | ||
| Q2 24 | $235.2M | $569.4M | ||
| Q1 24 | $223.2M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $3.4M | $-52.8M |
| 自由现金流率自由现金流/营收 | 11.4% | -174.0% |
| 资本支出强度资本支出/营收 | 8.1% | 1.7% |
| 现金转化率经营现金流/净利润 | 1.90× | — |
| 过去12个月自由现金流最近4个季度 | $33.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CWCORGNX
| Q4 25 | $5.8M | $-52.3M | ||
| Q3 25 | $15.4M | $-56.0M | ||
| Q2 25 | $8.8M | $-49.3M | ||
| Q1 25 | $11.8M | $33.6M | ||
| Q4 24 | $-742.0K | $-31.6M | ||
| Q3 24 | $10.4M | $-40.5M | ||
| Q2 24 | $21.0M | $-45.5M | ||
| Q1 24 | $6.0M | $-55.5M |
自由现金流CWCORGNX
| Q4 25 | $3.4M | $-52.8M | ||
| Q3 25 | $13.5M | $-56.5M | ||
| Q2 25 | $6.1M | $-49.7M | ||
| Q1 25 | $10.2M | $32.6M | ||
| Q4 24 | $-3.7M | $-32.7M | ||
| Q3 24 | $8.3M | $-40.9M | ||
| Q2 24 | $19.8M | $-46.0M | ||
| Q1 24 | $5.4M | $-56.0M |
自由现金流率CWCORGNX
| Q4 25 | 11.4% | -174.0% | ||
| Q3 25 | 38.4% | -189.9% | ||
| Q2 25 | 18.3% | -232.8% | ||
| Q1 25 | 30.1% | 36.6% | ||
| Q4 24 | -13.0% | -154.2% | ||
| Q3 24 | 24.9% | -168.9% | ||
| Q2 24 | 60.8% | -206.2% | ||
| Q1 24 | 13.7% | -358.5% |
资本支出强度CWCORGNX
| Q4 25 | 8.1% | 1.7% | ||
| Q3 25 | 5.5% | 1.7% | ||
| Q2 25 | 7.8% | 1.8% | ||
| Q1 25 | 4.7% | 1.2% | ||
| Q4 24 | 10.4% | 5.1% | ||
| Q3 24 | 6.1% | 1.3% | ||
| Q2 24 | 3.7% | 2.1% | ||
| Q1 24 | 1.3% | 3.6% |
现金转化率CWCORGNX
| Q4 25 | 1.90× | — | ||
| Q3 25 | 2.79× | — | ||
| Q2 25 | 1.72× | — | ||
| Q1 25 | 2.45× | 5.53× | ||
| Q4 24 | -0.47× | — | ||
| Q3 24 | 2.32× | — | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 0.92× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CWCO
| Services Revenues | $10.5M | 35% |
| Transferred At Point In Time | $8.5M | 29% |
| Operations And Maintenance | $8.4M | 28% |
| Transferred Over Time | $1.9M | 7% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
